In Vitro Characterization of a Liposomal Formulation of Celecoxib Containing 1,2-Distearoyl-sn-Glycero-3-Phosphocholine, Cholesterol, and Polyethylene Glycol and its Functional Effects Against Colorectal Cancer Cell Lines

Erdog, Asli; Limasale, Yanuar Dwi Putra; Keskin, Dilek; Tezcaner, Ayşen; Banerjee, Sreeparna

doi:10.1002/jps.23674

Cited by 11 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that the HT-29 cell death obtained from F9 (45%) is significantly higher than the 23 and 25% cell death reported for CBX encapsulated in large unilamellar vesicles (LUVs) and EGFR-targeted immune-liposomes, respectively [71]. F9-induced cell death is also significantly higher than that observed with CXB-loaded PEGylated liposomes by Erdo g et al [72], who demonstrated that CXB-loaded PEGylated liposomes reduced the viability of HT-29 cells by about 0, 35 and 45% after 24, 48 and 72 h of incubation using a final liposomal CXB concentration of 100 µM (higher than our concentration of 89.15 µM). Despite the fact that CXB has been reported by many researchers to inhibit the growth of HepG2 [73] and Daoy cells [74], we believe we are the first to show the effects of CXB nanoparticles on these two cell lines.…”

Section: Discussionmentioning

confidence: 70%

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

et al. 2022

View full text Add to dashboard Cite

This work aimed to optimize a celecoxib (CXB)-loaded solid lipid nanoparticles (SLN) colon delivery system for the enhancement of anticancer activity. An ultrasonic melt-emulsification method was employed in this work for the preparation of SLN. The physical attributes were characterized for their particle sizes, charges, morphology, and entrapment efficiency (%EE), in addition to DSC and FTIR. The in vitro drug release profiles were evaluated, and the anticancer activity was examined utilizing an MTT assay in three cancer cell lines: the colon cancer HT29, medulloblastoma Daoy, and hepatocellular carcinoma HepG2 cells. All of the prepared SLN formulations had nanoscale particle sizes ranging from 238 nm to 757 nm. High zeta-potential values (mv) within −30 s mv were reported. The %EE was in the range 86.76–96.6%. The amorphous nature of the SLN-entrapped CXB was confirmed from SLN DSC thermograms. The in vitro release profile revealed a slow constant rate of release with no burst release, which is unusual for SLN. Both the F9 and F14 demonstrated almost complete CXB release within 24 h, with only 25% completed within the first 5 h. F9 caused a significant percentage of cell death in the three cancer cell lines tested after 24 h of incubation and maintained this effect for 72 h. The prepared CXB-loaded SLN exhibited unique properties such as slow release with no burst and a high %EE. The anticancer activity of one formulation was extremely significant in all tested cancer cell lines at all incubation times, which is very promising.

show abstract

Section: Discussionmentioning

confidence: 70%

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

et al. 2022

View full text Add to dashboard Cite

show abstract

“…9 Similarly, liposomes can be used to increase the therapeutic efficacy of CXB while minimizing its severe cardiovascular toxicity. Erdoğet al 19 reported the encapsulation of CXB within the long-circulating liposomes and the effect of these formulations against colorectal cancer cell lines. In regard to the NBD peptides, though many investigations have revealed its broad range of anticancer activity, including adenocarcinoma, melanoma, prostate, and breast cancers, 17,20,21 direct administration of free peptides are not suitable for clinical application due to its instability and rapid clearance in vivo.…”

Section: Introductionmentioning

confidence: 99%

Cell Permeable NBD Peptide-Modified Liposomes by Hyaluronic Acid Coating for the Synergistic Targeted Therapy of Metastatic Inflammatory Breast Cancer

Sun

Zhang

et al. 2019

Mol. Pharmaceutics

View full text Add to dashboard Cite

Chronic inflammation is closely related to the development, deterioration, and metastasis of tumors. Recently, many studies have shown that down-regulating the expression of inflammation by blocking nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) pathways could significantly inhibit tumor growth and metastasis. The combined application of curcumin (CUR) and celecoxib (CXB) has been proven to exert a synergistic antitumor effect via inhibiting the activation of NF-κB and STAT3. TAT-NBD (TN) peptide, a fusion peptide of NF-κB essential modulator (NEMO)-binding domain peptide (NBD) and cell-penetrating peptide (TAT), can selectively block NF-κB activating pathway resulting in tumor growth inhibition. In the present study, a novel TN-modified liposome coloading both CXB and CUR (TN-CCLP) at a synergistic ratio was first constructed with the property of synchronous release, then hyaluronic acid (HA) as CD44 targeting moiety was coated on the surface of the cationic liposome via electrostatic interaction to prepare the anionic HA/TN-CCLP. In vitro results of cytotoxicity, macrophage migration inhibition, and anti-inflammation efficacy revealed that TN-CCLP and HA/TN-CCLP were significantly superior to TN-LP and CCLP, while TN-CCLP exhibited better effects than HA/TN-CCLP due to higher cellular uptake ability. Different from in vitro data, after systematically treating 4T1 breast tumor-bearing mice, HA/TN-CCLP exerted the most striking effects on anti-inflammation, inhibition of macrophage recruitment, and antitumor because of the longest circulation time and maximum tumor accumulation. In particular, HA/TN-CCLP could availably block the lung metastasis of breast cancer. Taken together, the novel CD44 targeted TN-CCLP exhibited the potential for inhibiting tumor development and metastasis through improving inflammatory infiltration of tumor tissue.

show abstract

“…[82] Liposomes are often used for increasing solubility of lipophilic drugs as these phospholipids can be dissolved in the cell membrane and thus promoting drug absorption from the intestine. Simon et al carried out transport studies in Caco-2 cells using digoxin as a P-gp substrate and performed calcein accumulation assay to assess P-gp expression in the presence of various phospholipids.…”

Section: Phospholipidsmentioning

confidence: 99%

Influence of excipients on drug absorption via modulation of intestinal transporters activity

Thakkar¹,

Desai²

2015

Asian J Pharm

View full text Add to dashboard Cite

O ne of the major factors affecting oral drug bioavailability is the activity of intestinal transport proteins, particularly for the drugs that undergo absorption by active transport mechanism. Many of the active pharmacological agents and the excipients used in their formulation are reported to modulate the activity of these transporters thereby either enhancing or decreasing the drug absorption and its systemic availability. These excipients are considered pharmacologically "inert" and have been used since years in pharmaceutical formulations. Appreciable interest is developing on the data demonstrating the role of excipients in altering the drug absorption across the intestine. Careful selection of the excipients thus is very important. A correctly chosen excipient can enhance the drug bioavailability and thus its therapeutic efficacy without increasing its dose. For locally acting drugs having systemic side effects, a proper excipient could lead to a decrease in its systemic absorption, thus reducing its side effects. This review focuses on the current findings of the excipients identified to modulate the activity of transporters, their mechanism of modulating the transporter's activity and various formulation strategies using these excipients to enhance drug absorption.

show abstract

In Vitro Characterization of a Liposomal Formulation of Celecoxib Containing 1,2-Distearoyl-sn-Glycero-3-Phosphocholine, Cholesterol, and Polyethylene Glycol and its Functional Effects Against Colorectal Cancer Cell Lines

Cited by 11 publications

References 39 publications

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity

Cell Permeable NBD Peptide-Modified Liposomes by Hyaluronic Acid Coating for the Synergistic Targeted Therapy of Metastatic Inflammatory Breast Cancer

Influence of excipients on drug absorption via modulation of intestinal transporters activity

Contact Info

Product

Resources

About